Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial.
Daniel Shao-Weng TanEnriqueta Felip FontGilberto de Castro JuniorBenjamin J SolomonAlastair GreystokeByoung Chul ChoManuel CoboTae Min KimSandip GangulyEnric CarcerenyLuis G Paz-AresJaafar BennounaMarina-Chiara GarassinoMichael SchenkerSang-We KimJan C BraseDenise Bury-MaynardVanessa Q PassosStéphanie DeudonBharani DharanYuanbo SongRafael CaparicaBruce E JohnsonPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
The addition of canakinumab to first-line pembrolizumab and CT did not prolong PFS or OS in patients with NSCLC.
Keyphrases
- advanced non small cell lung cancer
- phase iii
- epidermal growth factor receptor
- study protocol
- clinical trial
- image quality
- computed tomography
- phase ii
- contrast enhanced
- dual energy
- open label
- locally advanced
- double blind
- randomized controlled trial
- tyrosine kinase
- placebo controlled
- positron emission tomography
- small cell lung cancer
- squamous cell carcinoma
- magnetic resonance
- chemotherapy induced